Register Financial Advisors LLC Purchases 450 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Register Financial Advisors LLC boosted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 16.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,235 shares of the medical research company’s stock after purchasing an additional 450 shares during the period. Register Financial Advisors LLC’s holdings in Exact Sciences were worth $137,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Exact Sciences by 16.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 89,196 shares of the medical research company’s stock valued at $6,160,000 after purchasing an additional 12,349 shares during the last quarter. Thompson Investment Management Inc. grew its stake in shares of Exact Sciences by 13.1% during the first quarter. Thompson Investment Management Inc. now owns 160,584 shares of the medical research company’s stock worth $11,090,000 after buying an additional 18,595 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Exact Sciences by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 17,559,751 shares of the medical research company’s stock worth $1,299,070,000 after buying an additional 115,058 shares in the last quarter. New York Life Investment Management LLC lifted its stake in shares of Exact Sciences by 5.0% in the 4th quarter. New York Life Investment Management LLC now owns 21,106 shares of the medical research company’s stock valued at $1,561,000 after acquiring an additional 1,014 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in shares of Exact Sciences by 4.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 22,687 shares of the medical research company’s stock valued at $1,678,000 after acquiring an additional 1,020 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Trading Down 0.4 %

Shares of EXAS stock traded down $0.25 during mid-day trading on Friday, hitting $57.01. The company’s stock had a trading volume of 1,718,028 shares, compared to its average volume of 2,711,871. The company has a market cap of $10.52 billion, a PE ratio of -43.19 and a beta of 1.22. The company’s fifty day simple moving average is $46.37 and its 200-day simple moving average is $55.78. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.45 and a current ratio of 2.17. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $87.11.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. The firm had revenue of $699.26 million for the quarter, compared to analysts’ expectations of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.45) EPS. As a group, equities research analysts expect that Exact Sciences Co. will post -1.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on EXAS shares. The Goldman Sachs Group dropped their target price on Exact Sciences from $88.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, July 17th. Jefferies Financial Group began coverage on shares of Exact Sciences in a report on Monday, June 3rd. They issued a “buy” rating and a $75.00 price objective for the company. Benchmark reduced their target price on shares of Exact Sciences from $91.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Evercore ISI decreased their price target on shares of Exact Sciences from $80.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Finally, Scotiabank started coverage on shares of Exact Sciences in a report on Thursday, June 27th. They set a “sector outperform” rating and a $70.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, Exact Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $78.77.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.